2026. 05. 13
New C2H Report: Sacituzumab Govitecan (TRODELVY)
New C2H Report: Teprotumumab (TEPEZZA)
2026. 04. 08
New C2H Report: Brivaracetam (Briviact)
View all news
2019. 03. 06
International symposium - Current status and future role of HTA in Japan and other countries
View all events
View all reports